SEC Form 20-F filed by InMode Ltd.
$INMD
Biotechnology: Electromedical & Electrotherapeutic Apparatus
Health Care
Unavailable
Unavailable
Save time and jump to the most important pieces.
| Date | Price Target | Rating | Analyst |
|---|---|---|---|
| 4/29/2025 | Buy → Neutral | BTIG Research | |
| 4/28/2025 | $22.00 → $16.00 | Outperform → Neutral | Robert W. Baird |
| 10/17/2024 | $25.00 | Buy | BTIG Research |
| 7/23/2024 | $21.00 → $19.00 | Buy → Hold | Jefferies |
| 11/3/2023 | $52.00 → $24.00 | Buy → Neutral | UBS |
| 10/13/2023 | $55.00 → $22.00 | Buy → Hold | Canaccord Genuity |
| 3/29/2023 | $40.00 | Buy | UBS |
| 2/17/2023 | Buy → Hold | Needham |
In April 2025, Completed Recent Share Repurchase Program of 6.95 Million Shares YOKNEAM, Israel, April 28, 2025 /PRNewswire/ -- InMode Ltd. (NASDAQ:INMD) ("InMode"), a leading global provider of innovative medical technologies, today announced its consolidated financial results for the first quarter ended March 31, 2025. First Quarter 2025 Highlights: Quarterly GAAP revenues of $77.9 million, compared to $80.3 million in the first quarter of 2024.Quarterly revenues from consumables and service of $20.2 million, a decrease of 10% compared to the first quarter of 2024.GAAP operating income of $15.6 million, *non-GAAP operating income of $18.1 million.Total cash position of $512.9 million as
Conference call to be held on Monday, April 28, 2025, at 8:30 a.m. Eastern Time YOKNEAM, Israel, April 14, 2025 /PRNewswire/ -- InMode Ltd. (Nasdaq: INMD), a leading global provider of innovative medical technologies, announced today that it expects to release its financial results for the first quarter 2025 before the Nasdaq market opens on Monday, April 28, 2025. InMode is currently finalizing its financial results for the first quarter of 2025. While complete financial information and operating data are not yet available, set forth below are certain preliminary results of I
YOKNEAM, Israel, March 26, 2025 /PRNewswire/ -- InMode Ltd. (NASDAQ:INMD), a leading global provider of innovative medical technologies, today announced that Moshe Mizrahy, Chief Executive Officer, and Yair Malca, Chief Financial Officer, will present at the 24th Annual Needham Virtual Healthcare Conference on April 8, 2025. The fireside chat, moderated by Michael Matson, Senior Equity Analyst, is scheduled for 2:15 pm Eastern Time on Tuesday, April 8, and a live webcast of the presentation can be accessed here. InMode will also hold one-on-one investor meetings that same day. To schedule a meeting, please contact your Needham representative. For more information about the event, visit InMo
SC 13G/A - InMode Ltd. (0001742692) (Subject)
SC 13G/A - InMode Ltd. (0001742692) (Subject)
SC 13G - InMode Ltd. (0001742692) (Subject)
BTIG Research downgraded InMode from Buy to Neutral
Robert W. Baird downgraded InMode from Outperform to Neutral and set a new price target of $16.00 from $22.00 previously
BTIG Research initiated coverage of InMode with a rating of Buy and set a new price target of $25.00
In April 2025, Completed Recent Share Repurchase Program of 6.95 Million Shares YOKNEAM, Israel, April 28, 2025 /PRNewswire/ -- InMode Ltd. (NASDAQ:INMD) ("InMode"), a leading global provider of innovative medical technologies, today announced its consolidated financial results for the first quarter ended March 31, 2025. First Quarter 2025 Highlights: Quarterly GAAP revenues of $77.9 million, compared to $80.3 million in the first quarter of 2024.Quarterly revenues from consumables and service of $20.2 million, a decrease of 10% compared to the first quarter of 2024.GAAP operating income of $15.6 million, *non-GAAP operating income of $18.1 million.Total cash position of $512.9 million as
Conference call to be held on Monday, April 28, 2025, at 8:30 a.m. Eastern Time YOKNEAM, Israel, April 14, 2025 /PRNewswire/ -- InMode Ltd. (Nasdaq: INMD), a leading global provider of innovative medical technologies, announced today that it expects to release its financial results for the first quarter 2025 before the Nasdaq market opens on Monday, April 28, 2025. InMode is currently finalizing its financial results for the first quarter of 2025. While complete financial information and operating data are not yet available, set forth below are certain preliminary results of I
Clarifies Capital Allocation Strategy and Commitment to Shareholder Returns Refutes Misconceptions on Staffing and Production Asserts No Justification for Additional Legal Action YOKNEAM, Israel, March 6, 2025 /PRNewswire/ -- InMode Ltd. (NASDAQ:INMD) ("InMode"), a leading global provider of innovative medical technologies, today sent a letter to DOMA Perpetual Capital Management LLC ("DOMA") CEO and CIO Pedro Escudero in response to issues presented in his public letter dated January 15, 2025. The letter can be viewed here The full text of the letter follows: March 6, 2025 Mr. Pedro EscuderoCEO and CIODOMA Perpetual Capital Management LLC Dear Mr. Escudero, As CEO of InMode, I felt it was
6-K - InMode Ltd. (0001742692) (Filer)
6-K - InMode Ltd. (0001742692) (Filer)
6-K/A - InMode Ltd. (0001742692) (Filer)